Skip to main content
ConductScienceScienceDex

Sean Wasserman

NIH Rank #7361
Unclaimed recordClaim profile
  • Program Leader
  • Early Career

Researcher identity and coverage

Current affiliation
Not verified in ScienceDex.NIH award organizations may differ from a researcher's employer.
NIH RePORTER identity
Profile ID 80311364Search this ID in NIH RePORTER
ScienceDex PI coverage
FY2026 onlyCareer claims are limited to the years shown.

NIH Funding · FY2026

Linked Award Amount
$1.2M
Full award amounts, FY2026
Award Records
3
Records listing this PI
Award-Linked Rank
#7,361
By linked amount among FY2026 PIs
Earliest Year Loaded
2026
ScienceDex PI coverage

One scientist record

NIH portfolios and SHARE

This is the common ScienceDex page for Sean Wasserman. NIH portfolio memberships are contextual views of this scientist, while SHARE Score, S-Index, and S-Impact describe the researcher's global sharing track record.

Review metric definitions

FY2026 NIH portfolio memberships

No institute-level portfolio release is available for this scientist and fiscal year yet. Existing award history remains unchanged above.

Researcher-associated datasets

These datasets are linked to this researcher's ShareScore identity. This does not by itself prove that an NIH portfolio funded each dataset.

No compatible author-to-dataset release is published. Dataset records are unavailable, not zero.

Award data coverage

ScienceDex currently has one fiscal year of PI ranking data for this record. This does not establish the first NIH award or current employer.

Single fiscal year on record (FY2026): $1.2M in linked award amounts across 3 award records · Award-linked rank #7361.

FY2026 award records by amount

NIH award records listing Sean Wasserman as a PI. Multi-PI records show the full award amount for context.

  • 4U01AI170426-05U01
    PRESCIENT: A phase IIc, open-label, randomized controlled trial of ultra-short course bedaquiline, clofazimine, pyrazinamide and delamanid versus standard therapy for drug-susceptible tuberculosis
    Brigham and Women's Hospital
    $526.3K
    award amount
  • 3U01AI170426-05S2U01
    PRESCIENT: A phase IIc, open-label, randomized controlled trial of ultra-short course bedaquiline, clofazimine, pyrazinamide and delamanid versus standard therapy for drug-susceptible tuberculosis
    Brigham and Women's Hospital
    $365.4K
    award amount
  • 3U01AI170426-05S1U01
    PRESCIENT: A phase IIc, open-label, randomized controlled trial of ultra-short course bedaquiline, clofazimine, pyrazinamide and delamanid versus standard therapy for drug-susceptible tuberculosis
    Brigham and Women's Hospital
    $331K
    award amount

Award organization

Organizations that administered FY2026 awards listing Sean Wasserman as a PI.

FY2026 award administered by Brigham and Women's Hospital (MA).

Coverage and award-record milestones

Computed from the fiscal years currently available in ScienceDex.

  1. 2026
    First NIH Award
    Brigham and Women's Hospital
  2. 2026
    $500K Cumulative Funding
  3. 2026
    $1M Cumulative Funding
  4. 2026
    Entered Top 50% Nationally
    Ranked #7361

Shared-award investigators

Other investigators listed on at least one of the same NIH award records as Sean Wasserman.

Serena Patricia Koenig
Brigham and Women's Hospital
3
shared awards

Explore further

Find collaborators for Sean Wasserman

Search NIH-funded principal investigators by topic, department, or activity.

Open Find Collaborators →

Benchmark grant budgets

Compare median NIH grant budgets across departments, mechanisms, and years.

Open Grant Budget Benchmark →